PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)267-273
Number of pages7
JournalRadiotherapy and Oncology
Volume122
Issue number2
DOIs
Publication statusPublished - Feb 2017

Keywords

  • Zr-89-cetuximab
  • EGFR
  • Immuno-PET
  • Phase I trial
  • GROWTH-FACTOR RECEPTOR
  • MONOCLONAL-ANTIBODIES
  • PLUS CETUXIMAB
  • 1ST-LINE CHEMOTHERAPY
  • EGFR-INHIBITION
  • IMMUNO-PET
  • EXPRESSION
  • RADIOTHERAPY
  • CARCINOMA
  • SURVIVAL

Cite this